EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie

Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results

Nuriye Ozlem Kucuk, Nazim Coskun, Mine Araz, Nalan Alan Selcuk, Kezban Berberoglu, Elif Cingi Ozdemir, Fikriye Gul Gumuser, Serkan Kuyumcu, Ceren Sezgin, Ozgur Sanli, Yasemin Sanli, Mehmet Ali Nahit Sendur und 1 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.270952 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Nuriye Ozlem Kucuk und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

161Tb is a theranostic radionuclide that emits both β- particles and Auger electrons with high linear energy transfer, potentially enhancing cytotoxicity in micrometastatic disease. We report the first multicenter clinical experience of [161Tb]Tb-PSMA in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to [177Lu]Lu-PSMA therapy.

Methods

This prospective, multicenter study included 7 patients with mCRPC who had progressed despite prior androgen receptor pathway inhibitors, taxane-based chemotherapy, and at least 2 cycles of [177Lu]Lu-PSMA. All patients had PSMA-positive disease without any [18F]FDG-discordant lesions. Each received 2 cycles of [161Tb]Tb-PSMA (7.4 GBq per cycle, 6-wk interval). Response was assessed with [68Ga]Ga-PSMA PET/CT per RECIP 1.0 and prostate-specific antigen kinetics. Posttherapy dosimetry was performed using SPECT/CT imaging at 4 time points.

Results

Of the 7 patients, 4 (57%) demonstrated objective imaging response and 4 (57%) showed at least a 50% decline in prostate-specific antigen levels. Treatment was well tolerated, with only mild adverse events (grades 1-2) and no toxicity greater than grade 3. Organ dosimetry confirmed favorable absorbed dose distributions. Conclusion: [161Tb]Tb-PSMA demonstrated promising molecular and biochemical activity with a favorable safety profile in patients who had progressed after [177Lu]Lu-PSMA therapy. These preliminary findings support further investigation of 161Tb-based radiopharmaceuticals as next-generation therapeutic options for mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumHumansMaleAgedMiddle AgedNeoplasm MetastasisRadioisotopesTreatment OutcomePositron Emission Tomography Computed TomographyRadiopharmaceuticalsProspective StudiesGlutamate Carboxypeptidase IIAged, 80 and overHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Stichwörter der Autor:innen

161Tbmetastatic castration-resistant prostate cancerprostate-specific membrane antigen

Substanzen

LutetiumLutetium-177RadioisotopesPluvictoRadiopharmaceuticalsGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Turkey.
  • Department of Nuclear Medicine, Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey; nazimcoskun@aybu.edu.tr.
  • Faculty of Medicine, Department of Nuclear Medicine, Yeditepe University, Istanbul, Turkey.
  • Department of Nuclear Medicine, Anadolu Medical Center, Istanbul, Turkey.
  • Department of Nuclear Medicine, Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Faculty of Medicine, Department of Nuclear Medicine, Manisa Celal Bayar University, Manisa, Turkey.

Zitieren

APA

Kucuk, N. O., Coskun, N., Araz, M., Alan Selcuk, N., Berberoglu, K., Ozdemir, E. C., Gumuser, F. G., Kuyumcu, S., Sezgin, C., Sanli, O., Sanli, Y., Sendur, M. A. N., & Urun, Y. (2025). Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270952

Vancouver

Kucuk NO, Coskun N, Araz M, Alan Selcuk N, Berberoglu K, Ozdemir EC, et al. Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270952

BibTeX
@article{Kucuk2025,
  author = {Kucuk, Nuriye Ozlem and Coskun, Nazim and Araz, Mine and Alan Selcuk, Nalan and Berberoglu, Kezban and Ozdemir, Elif Cingi and Gumuser, Fikriye Gul and Kuyumcu, Serkan and Sezgin, Ceren and Sanli, Ozgur and Sanli, Yasemin and Sendur, Mehmet Ali Nahit and Urun, Yuksel},
  title = {Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.270952}
}
Kostenlos starten →